Brahmi

Bacopa monnieri
Brahmi (Bacopa monnieri) is a revered herb in Ayurveda, native to South Asia. Traditionally, it's claimed to enhance cognitive functions and support overall brain health. This creeping perennial herb is widely recognized for its supposed nootropic and adaptogenic properties, often found in marshy environments and used in various Ayurvedic formulations for mental well-being.
PLANT FAMILY
Plantaginaceae (Plantain)
PARTS USED
Whole plant
AYURVEDIC ACTION
Vata ↓, Pitta ↓, Kapha ↓
ACTIVE COMPOUNDS
Bacosides (2-3%)

What is Brahmi?

Brahmi, also known as Bacopa monnieri, is a creeping perennial herb indigenous to wetlands across South Asia, including India, Nepal, and Sri Lanka. This small, succulent plant with oval leaves and tiny white flowers thrives in marshy environments and is widely recognized for its historical use in traditional Ayurvedic medicine, where it has been revered for centuries as a potent nootropic and adaptogen.

Its efficacy is attributed to active compounds called bacosides, which are believed to enhance cognitive functions and support overall brain health, making it a subject of increasing scientific interest in modern herbalism. While not a plant, X in the question does not refer to the name of the plant. Since there is no other reference to "X", I will list other names of Brahmi instead.

Other Names of Brahmi

  • Bacopa
  • Water Hyssop
  • Thyme-leafed Gratiola
  • Indian Pennywort
Starr 010818-0007 Bacopa monnieri

Benefits of Brahmi

Heading

<h3> Absolute Contraindications of Brahmi </h3> <h4> Pregnancy or Breastfeeding [Avoid during pregnancy or while nursing]</h4> <ul> <li>🤰</li> <li>Recommendation: Avoid using Bacopa while pregnant or breastfeeding; discuss alternatives with your clinician.</li> <li>Reasoning: Human safety data are limited and most authoritative safety reviews recommend avoiding or using caution because there is insufficient evidence to confirm safety for the fetus or infant.</li> <li>Scientific_Study_Title: Bacopa monnieri - LiverTox (NCBI Bookshelf review)</li> <li>Scientific_Study_Authors: LiverTox authors / National Institute of Diabetes and Digestive and Kidney Diseases (LiverTox editorial)</li> <li>Scientific_Study_Link: https://www.ncbi.nlm.nih.gov/books/NBK603563/</li> <li>Scientific_Study_Excerpt: <p>Major safety reviews note that Bacopa has not been studied in pregnancy and that there is not enough reliable information to confirm safety during pregnancy or lactation. Clinical trial data in humans are limited, and authoritative herbal safety references recommend avoiding use in pregnancy and breastfeeding due to insufficient evidence about fetal or neonatal effects. Practically, caution is advised because many supplement components lack reproductive-safety data and because formulations can be variable.</p> </li> </ul> <h4> Severe hypotension or unstable cardiovascular collapse [If you have very low blood pressure or are hemodynamically unstable]</h4> <ul> <li>⚠️</li> <li>Recommendation: Do not take Bacopa if you have symptomatic low blood pressure or are being treated for acute unstable hypotension without direct medical supervision.</li> <li>Reasoning: Experimental studies demonstrate dose-dependent vasodilation and acute hypotensive effects; in vulnerable patients this could worsen perfusion or cause syncope.</li> <li>Scientific_Study_Title: Bacopa monnieri and its constituents is hypotensive in anaesthetized rats and vasodilator in various artery types</li> <li>Scientific_Study_Authors: Singh R, et al. (study authors as listed on PubMed)</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/21762768/</li> <li>Scientific_Study_Excerpt: <p>Preclinical intravenous dosing produced dose-dependent decreases in systolic and diastolic blood pressures in anaesthetized animals and showed direct vasorelaxation across arterial types. Mechanisms included endothelial nitric oxide release and effects on calcium handling in smooth muscle. These acute vasodilatory effects demonstrate that Bacopa can lower blood pressure under some conditions, suggesting risk for individuals with already low or unstable blood pressure.</p> </li> </ul> <h4> Documented severe liver reaction to a Bacopa-containing product [Prior severe liver injury attributed to an Ayurvedic product containing Brahmi]</h4> <ul> <li>🫗</li> <li>Recommendation: Do not re-expose if you previously had a severe liver injury that was attributed to a preparation containing Bacopa; seek specialist advice before any re-challenge.</li> <li>Reasoning: Although overall human hepatotoxicity reports are rare, structured causality assessment identified severe hepatotoxicity temporally linked to Ayurvedic regimens that included a product labeled as “Brahmi” in at least one case; this supports avoidance after a prior serious reaction.</li> <li>Scientific_Study_Title: Severe hepatotoxicity by Indian Ayurvedic herbal products: a structured causality assessment</li> <li>Scientific_Study_Authors: Teschke R, Bahre R (and co-authors)</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/19841509/</li> <li>Scientific_Study_Excerpt: <p>A patient treated with multiple Ayurvedic herbal products, including a formulation labeled “Brahmi,” developed severe hepatotoxicity with marked ALT/AST elevations and hyperbilirubinemia that improved after stopping the products. Causality assessment found probable links to some components and possible contribution from others including the product described as Brahmi. The report highlights difficulty in attributing causality in multi-herbal regimens but documents real clinical hepatotoxic presentations associated with Ayurvedic products.</p> </li> </ul> <h3> Relative Contraindications of Brahmi </h3> <h4> Thyroid disorders / Thyroid hormone therapy (hypo- or hyperthyroid patients on levothyroxine or liothyronine)</h4> <ul> <li>🧾</li> <li>Recommendation: Use only with medical supervision and frequent thyroid function monitoring; consider avoiding if you require tightly titrated thyroid hormone dosing.</li> <li>Reasoning: Animal studies show Bacopa extracts can alter thyroid hormone levels (e.g., increasing T4 in mice), suggesting it may change thyroid hormone status or interact with replacement/antithyroid drugs.</li> <li>Scientific_Study_Title: Relative efficacy of three medicinal plant extracts in the alteration of thyroid hormone concentrations in male mice</li> <li>Scientific_Study_Authors: K. K. R. (as listed on PubMed) - (authors per PubMed record)</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/12065164/</li> <li>Scientific_Study_Excerpt: <p>In a controlled mouse experiment, Bacopa monnieri extract increased serum T4 concentrations (approximately a 41% increase compared with control) while other plant extracts had different effects on T3/T4. These findings indicate Bacopa can influence thyroid hormone levels in animals and support clinical caution and monitoring when Bacopa is used by people taking thyroid medications or with labile thyroid conditions.</p> </li> </ul> <h4> Concurrent use of cholinergic drugs (e.g., muscarinic agonists or cholinesterase inhibitors)</h4> <ul> <li>🔗</li> <li>Recommendation: Avoid combining without medical advice; monitor closely for signs of excessive cholinergic activity (nausea, sweating, bradycardia, diarrhea, salivation).</li> <li>Reasoning: Bacopa exhibits acetylcholinesterase inhibitory activity; combining it with cholinergic medications can potentiates cholinergic effects and, in at least one case report, was linked to cholinergic toxicity when taken with a muscarinic agonist.</li> <li>Scientific_Study_Title: Suspected cholinergic toxicity due to cevimeline hydrochloride and Bacopa monnieri interaction: a case report</li> <li>Scientific_Study_Authors: Acquarulo B, Tandon P, Macica CM</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/35765109/</li> <li>Scientific_Study_Excerpt: <p>A published case report described a patient on the muscarinic agonist cevimeline who developed nausea, sweating and tachycardia after taking a supplement containing Bacopa monnieri. Clinical improvement occurred after stopping the supplement. The authors discuss Bacopa’s ability to affect cholinergic pathways and CYP enzymes as plausible mechanisms for potentiating drug effects, supporting caution when combining cholinergic agents with Bacopa.</p> </li> </ul> <h4> Co-administration with drugs metabolized by CYP3A4, CYP2C9 or CYP2C19 (e.g., certain statins, warfarin, some antiepileptics and proton-pump inhibitors)</h4> <ul> <li>💊</li> <li>Recommendation: Consult your prescribing clinician before starting Bacopa; monitoring drug levels or clinical markers (INR for warfarin, etc.) is advised if combined.</li> <li>Reasoning: In vitro data show whole Bacopa extracts can inhibit multiple CYP enzymes important for drug metabolism, which could raise blood levels of drugs that rely on these enzymes, increasing adverse-effect risk.</li> <li>Scientific_Study_Title: Inhibition of human cytochrome P450 enzymes by Bacopa monnieri standardized extract and constituents</li> <li>Scientific_Study_Authors: Bhattacharyya S, et al. (as listed on PubMed)</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/24566323/</li> <li>Scientific_Study_Excerpt: <p>In vitro assays showed that Bacopa monnieri extract non-competitively inhibited CYP2C19, CYP2C9 and CYP1A2 and competitively inhibited CYP3A4 at concentrations estimated to be achievable in the gut after oral dosing. The authors note whole extracts (more than isolated bacosides) showed the strongest inhibition and suggest potential for herb-drug interactions when co-administered with drugs cleared by these CYPs.</p> </li> </ul>

Heading

<h4> Gastrointestinal upset (nausea, abdominal cramps, increased stool frequency)</h4> <ul> <li>🤢</li> <li>Side effect summary: Many human trials report mild stomach-related side effects - nausea, cramping, loose stools or increased bowel movements - usually transient and dose-related.</li> <li>Recommendation: Take Bacopa with food, reduce dose if needed, and consult a clinician if symptoms persist or are severe.</li> <li>Reasoning: Clinical trials and randomized studies repeatedly note gastrointestinal complaints as the most common adverse events, often resolving with continued use or dose adjustment.</li> <li>Severity Level: Mild</li> <li>Scientific_Study_Available: Yes</li> <li>Scientific_Study_Title: Does Bacopa monnieri improve memory performance in older persons? Results of a randomized, placebo-controlled, double-blind trial</li> <li>Scientific_Study_Authors: Stough C, et al.</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/20590480/</li> <li>Scientific_Study_Excerpt: <p>In this randomized trial, Bacopa significantly improved measures of memory but was associated with gastrointestinal adverse effects: increased stool frequency, abdominal cramps and nausea were reported more often in the Bacopa group than placebo. The authors conclude these GI effects were generally mild and manageable, consistent with other clinical trials of Bacopa in elderly and adult populations.</p> </li> </ul> <h4> Dizziness or lowered blood pressure (lightheadedness, fainting risk)</h4> <ul> <li>🩺</li> <li>Side effect summary: Some experimental and clinical data indicate vasodilatory properties which can cause dizziness or lightheadedness, especially with higher or acute doses.</li> <li>Recommendation: If you feel lightheaded, stop taking Bacopa and seek medical advice; avoid driving or operating heavy machinery until you know how it affects you. Those on blood-pressure medications should consult a clinician first.</li> <li>Reasoning: Animal and some human physiological studies demonstrate vasodilation and occasional reductions in heart rate or blood pressure; this can translate clinically to symptomatic hypotension in susceptible individuals.</li> <li>Severity Level: Moderate</li> <li>Scientific_Study_Available: Yes</li> <li>Scientific_Study_Title: Bacopa monnieri and its constituents is hypotensive in anaesthetized rats and vasodilator in various artery types</li> <li>Scientific_Study_Authors: Utreja P, et al. (authors as listed in PubMed)</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/21762768/</li> <li>Scientific_Study_Excerpt: <p>Intravenous Bacopa extract produced dose-dependent decreases in systolic and diastolic pressures in anaesthetized rats and caused relaxation in multiple isolated artery types. The study demonstrates nitric-oxide mediated endothelial effects and alterations in calcium handling as likely mechanisms. Translationally, these vascular actions indicate a plausible mechanism for dizziness or symptomatic hypotension in humans, especially with high or acute dosing or when combined with antihypertensive drugs.</p> </li> </ul> <h4> Rare liver injury (very uncommon; idiosyncratic)</h4> <ul> <li>🧪</li> <li>Side effect summary: Clinically apparent liver injury attributed specifically to Bacopa is rare; however, some case reports implicate multi-herb Ayurvedic regimens that included a product labeled as “Brahmi.”</li> <li>Recommendation: If you develop jaundice, dark urine, severe fatigue, or abdominal pain while taking Bacopa, stop it and seek urgent medical evaluation with liver tests.</li> <li>Reasoning: Although systematic reviews and liver safety databases find Bacopa is rarely linked to liver injury, isolated reports and causality assessments exist for Ayurvedic multi-herbal products that included Brahmi, so vigilance is warranted.</li> <li>Severity Level: Moderate</li> <li>Scientific_Study_Available: Yes</li> <li>Scientific_Study_Title: Severe hepatotoxicity by Indian Ayurvedic herbal products: a structured causality assessment</li> <li>Scientific_Study_Authors: Teschke R, Bahre R</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/19841509/</li> <li>Scientific_Study_Excerpt: <p>A case report documented a patient using multiple Ayurvedic products (one described as “Brahmi”) who developed marked liver enzyme elevations and jaundice that improved after stopping the products. While causality assessment favored some other herbs as most likely responsible, the case underlines that multi-herb Ayurvedic products can cause serious liver injury and that individual components may contribute in some cases.</p> </li> </ul>

Heading

<h4>Thyroid hormone replacement (levothyroxine, liothyronine)</h4> <ul> <li>Interaction_Details: Bacopa extracts altered thyroid hormone concentrations in animal studies (reported increases in T4), which suggests Bacopa may alter thyroid status or the effect of thyroid replacement drugs.</li> <li>Severity: Moderate</li> <li>Recommendation: If you take thyroid hormone, consult your clinician before starting Bacopa and monitor thyroid function tests more frequently while using it.</li> <li>Scientific_Study_Available: Yes</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/12065164/</li> <li>Scientific_Study_Title: Relative efficacy of three medicinal plant extracts in the alteration of thyroid hormone concentrations in male mice</li> <li>Scientfic_Study_Authors: (authors as listed on PubMed)</li> <li>Scientific_Study_Excerpt: <p>In this controlled animal study Bacopa monnieri extract increased serum T4 concentrations compared with control animals, implying a thyroid-stimulating action in mice. The findings indicate a potential for Bacopa to influence thyroid hormone levels in vivo and thus to modify the pharmacologic needs of patients on thyroid replacement or antithyroid drugs; clinical monitoring is therefore recommended if combined.</p> </li> </ul> <h4>Cholinergic agents and cholinesterase inhibitors (e.g., donepezil, galantamine, rivastigmine, cevimeline)</h4> <ul> <li>Interaction_Details: Bacopa inhibits acetylcholinesterase and modulates cholinergic transmission; co-use with cholinergic drugs or muscarinic agonists can potentiate cholinergic effects (nausea, sweating, bradycardia, diarrhea).</li> <li>Severity: Moderate</li> <li>Recommendation: Avoid combined use unless supervised by a clinician; monitor for cholinergic symptoms and adjust doses as necessary.</li> <li>Scientific_Study_Available: Yes</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/35765109/</li> <li>Scientific_Study_Title: Suspected cholinergic toxicity due to cevimeline hydrochloride and Bacopa monnieri interaction: a case report</li> <li>Scientfic_Study_Authors: Acquarulo B, Tandon P, Macica CM</li> <li>Scientific_Study_Excerpt: <p>A clinical case report describes a patient on cevimeline who experienced cholinergic symptoms after taking a supplement containing Bacopa monnieri; symptoms improved on discontinuation. Combined with in vitro and in vivo evidence that Bacopa inhibits acetylcholinesterase, the case supports an interaction risk when Bacopa is combined with other cholinergic drugs.</p> </li> </ul> <h4>Drugs metabolized by CYP3A4, CYP2C9, CYP2C19 (e.g., warfarin, some statins, certain antiepileptics and PPIs)</h4> <ul> <li>Interaction_Details: Whole-extract Bacopa can inhibit intestinal CYP enzymes in vitro, potentially increasing blood levels of drugs metabolised by those enzymes and raising adverse-effect risk.</li> <li>Severity: Moderate</li> <li>Recommendation: Consult your clinician or pharmacist before combining Bacopa with drugs that have narrow therapeutic ranges or are primarily metabolized by CYP3A4/CYP2C9/CYP2C19; consider monitoring drug levels or clinical markers (e.g., INR for warfarin).</li> <li>Scientific_Study_Available: Yes</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/24566323/</li> <li>Scientific_Study_Title: Inhibition of human cytochrome P450 enzymes by Bacopa monnieri standardized extract and constituents</li> <li>Scientfic_Study_Authors: Bhattacharyya S, et al.</li> <li>Scientific_Study_Excerpt: <p>In vitro experiments showed that Bacopa monnieri whole extract inhibited activities of CYP2C19, CYP2C9, CYP1A2 and competitively inhibited CYP3A4 at concentrations projected to be present in the gut after oral dosing. The investigators caution about potential herb-drug interactions, particularly for orally administered drugs largely metabolized by these CYP isoforms.</p> </li> </ul> <h4>Antihypertensive medications (ACE inhibitors, ARBs, beta-blockers, calcium-channel blockers)</h4> <ul> <li>Interaction_Details: Because Bacopa can produce vasodilation and reduce blood pressure in experimental models, combining it with antihypertensives could produce additive blood-pressure lowering and symptomatic hypotension.</li> <li>Severity: Mild</li> <li>Recommendation: Use with caution; monitor blood pressure regularly and report symptoms like fainting or extreme lightheadedness to your clinician.</li> <li>Scientific_Study_Available: Yes</li> <li>Scientific_Study_Link: https://pubmed.ncbi.nlm.nih.gov/21762768/</li> <li>Scientific_Study_Title: Bacopa monnieri and its constituents is hypotensive in anaesthetized rats and vasodilator in various artery types</li> <li>Scientfic_Study_Authors: Utreja P, et al.</li> <li>Scientific_Study_Excerpt: <p>Experimental intravenous dosing lowered systolic and diastolic pressures in animals and produced direct vasorelaxation in multiple arterial beds through endothelial and smooth muscle mechanisms. The study suggests a plausible additive hypotensive effect when Bacopa is combined with clinical antihypertensive drugs, warranting monitoring and dose adjustments where appropriate.</p> </li> </ul>